Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
68.24
+0.21 (0.31%)
At close: Apr 2, 2025, 4:00 PM
66.52
-1.72 (-2.52%)
After-hours: Apr 2, 2025, 7:59 PM EDT
Novo Nordisk Employees
Novo Nordisk had 77,349 employees as of December 31, 2024. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
$521,201
Profits / Employee
$181,248
Market Cap
301.38B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
Dec 31, 2019 | 43,258 | 56 | 0.13% |
Dec 31, 2018 | 43,202 | 520 | 1.22% |
Dec 31, 2017 | 42,682 | 711 | 1.69% |
Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
Dec 31, 2015 | 40,638 | -319 | -0.78% |
Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
Dec 31, 2003 | 18,756 | 751 | 4.17% |
Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
Dec 31, 1999 | 11,994 | 345 | 2.96% |
Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NVO News
- 1 hour ago - Novo Nordisk's head of commercial strategy steps down - Reuters
- 2 hours ago - Novo Nordisk announces changes in Executive Management - GlobeNewsWire
- 1 day ago - Coffers swelling on Wegovy sales, Novo Holdings doubles income and returns in 2024 - Reuters
- 2 days ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 3 days ago - Novo Nordisk: Finally A Buying Opportunity - Seeking Alpha
- 3 days ago - Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors - Seeking Alpha
- 4 days ago - Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 - GlobeNewsWire
- 4 days ago - Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years - CNBC